Order Reagents

Trans-Booster:
Enhancer to Boost the Transfection Efficiency of DNA and mRNA

$106.00$190.00 USD

  • Attachment-dependent and suspension growing cells such as 293T, MDA-231 and Jurkat cells
  • Optimized for pDNA and mRNA transfection in a variety of cell types
Clear

Trans-Booster: Enhancer for Transient Transfection of Attachment-Dependent and Suspension-Growing Cells

Trans-Booster is a highly effective reagent to enhance the transfection efficiency in different cell types. Trans-Booster is a synthetic polymer that is specifically tailored for DNA delivery. Co-incubation with DNA molecules and RJH transfection reagents results in 100-200 nm particles with a net charge that depends on the relative ratio of each reagent. The Trans-Booster is designed to work with aqueous buffers, obviating the need for organic solvents during complex preparation. Trans-Booster is a non-integrating reagent so that the genetic make-up of host cells is not altered after treatment with the transfection reagent. Trans-Booster has been tested and found effective in different types of attachment-dependent and suspension-growing cells (see list below). Trans-Booster was also found to help with siRNA mediated silencing and microRNA mediated cell modulation, but the effectiveness is usually less in these cases and depends on specific cell types. As with all transfection reagents, formulation of Trans-Booster with DNA may need to be optimized for specific cell types and nucleic acids.

Overview:

Property Trans-Booster
Technology Polymeric
Nucleic Acid pDNA
Cell Types Attachment dependent and suspension-growing
Transfection Type Transient
High Throughput Compatible
Serum Compatible
Buffer Aqueous
Storage Temperature -20 ºC
Shelf Life at -20 ºC ~1 year

Transfections per 1  mL of Trans-Booster:

Plate Size Number of Transfections
6-well (1200 µL/well) 40 – 330
24-well (800 µL/well) 60 – 500
48-well (400 µL/well) 125 – 1000
96-well (200 µL/well) 250 – 2000

Validated Cell Types:

Human T-cells (Jurkat)
Kidney fibroblast cells (293-T)
Breast cancer cells (MDA-231 and MCF-7)
Human Leukemia cells (K562)
Vascular Smooth Muscle Cells (VSMCs)
Human Umbilical Vein Endothelial Cells (HUVECs)
Bone Marrow Derived Mesenchymal Stem Cells (BM-MSC)
Umbilical Cord Blood Derived Mesenchymal Stem Cells (UCB-MSC)

References

Naemnark et al., Molecular Pharmaceutics (2009) 6: 1798-1815.

Clements et al., Clinical Orthopeadics and Related Research (2009) 467: 3129-3137.
%d bloggers like this: